Study in Pediatric Subjects With Peanut Allergy to Evaluate Efficacy and Safety of Dupilumab as Adjunct to AR101 (Peanut Oral Immunotherapy)

Exclusion Criteria

• •History of other chronic disease (other than asthma, Atopic Dermatitis (AD), or allergic rhinitis) requiring therapy (eg, heart disease, diabetes, hypertension) that would represent a risk to participant's health or safety in this study or ability to comply with study protocol
• •History of frequent or recent severe, life-threatening episode of anaphylaxis or anaphylactic shock
• •History of eosinophilic Gastrointestinal (GI) disease
• •Asthma at time of enrollment with any of the following:
• •* Forced Expiratory Volume 1 Second (FEV1) \<80% of predicted or ratio of FEV1 to forced vital capacity (FEV1/FVC) \<75% of predicted with or without controller medications
• •* Inhaled corticosteroids (ICS) dosing of daily fluticasone (or equivalent ICS based on NHLBI dosing chart)
• •* One hospitalization in the past year for asthma
• •* Emergency room visit for asthma within 6 months prior to screening
• •Use of systemic corticosteroids within 2 months prior to screening
• •Use of other forms of allergen immunotherapy or immunomodulatory therapy within 3 months prior to screening
• •Use of any agents known or likely to interact with epinephrine (eg, beta-blockers, angiotensin converting enzyme-inhibitors, tri-cyclic antidepressants, or other drugs), within 3 weeks prior to screening
• •Allergy to oat (placebo in DBPCFC)